Advanced search

Authors whose works are in public domain in at least one jurisdiction

List of works by Jonathan M. Brotchie

1-50 of 148 results

View this query on the Wikidata Query Service
Levodopa-induced dyskinesias

scientific article
Presymptomatic compensation in Parkinson's disease is not dopamine-mediated

scientific article
Novel pharmacological targets for the treatment of Parkinson's disease

scientific article published on October 2006
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study

scientific article published on December 11, 2001
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease

scientific article published on 10 January 2013
Nondopaminergic mechanisms in levodopa-induced dyskinesia

scientific article
Characterization of Enhanced Behavioral Responses tol-DOPA Following Repeated Administration in the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson's Disease

scientific article published on June 1, 1998
CB1 cannabinoid receptor signalling in Parkinson's disease

scientific article
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.

scientific article published on February 1999
Serotonin and Parkinson's disease: On movement, mood, and madness

scientific article published on July 2009
The serotonergic system in Parkinson's disease

scientific article published on 22 August 2011
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease

scientific article published on 13 May 2005
Dietary resveratrol administration increases MnSOD expression and activity in mouse brain.

scientific article published on 16 May 2008
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease

scientific article published in November 2002
Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus.

scientific article published in July 1996
The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future

scientific article published on January 2010
Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

scientific article published in August 2003
Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

scientific article published on 15 March 2010
Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice

scientific article published on 25 January 2008
Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

scientific article published on July 2010
Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices.

scientific article published in April 1997
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease

scientific article published in October 2003
Levodopa-induced dyskinesia in Parkinson's disease.

scientific article
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease

scientific article published on 01 September 2000
Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes.

scientific article published on April 1995
Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials

scientific article published on 05 December 2012
Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model t

scientific article
Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease

scientific article published on 14 May 2015
Animal models of α-synucleinopathy for Parkinson disease drug development

scientific article
Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure

scientific article published on October 2006
Non-dopaminergic treatments in development for Parkinson's disease

scientific article published on October 2008
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

scientific article published in September 2001
α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.

scientific article published on 21 October 2016
Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia.

scientific article
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

scientific article
Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein

scientific article
Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

scientific article published in May 1998
Dihydropyridine calcium channel blockers and the progression of parkinsonism

scientific article published in March 2012
Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.

scientific article published in June 2001
Striatal histone modifications in models of levodopa-induced dyskinesia

scientific article
Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate.

scientific article published in February 2010
Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models

scientific article published on 27 August 2014
Mechanisms compensating for dopamine loss in early Parkinson disease

scientific article published on February 2009
Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease.

scientific article published in June 1995
Management of impulse control disorders in Parkinson's disease: Controversies and future approaches

scientific article published on 21 January 2015
PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.

scientific article
The Cannabinoid Receptor Agonist WIN 55,212-2 Reduces D2, but Not D1, Dopamine Receptor-Mediated Alleviation of Akinesia in the Reserpine-Treated Rat Model of Parkinson's Disease

scientific article published on November 1, 1997
Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia

scientific article
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.

scientific article published in July 2001
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.

scientific article

Paulina is supported by:

About Paulina

Help